Products
Panitumumab is commercially available as an infusion solution (Vectibix). It has been approved in many countries since 2008.
Structure and properties
Panitumumab is a recombinant, fully human IgG2 monoclonal antibody against EGFR.
Effects
Panitumumab (ATC L01XC08) has antitumor and antiangiogenic properties. The effects are due to binding to the epidermal growth factor receptor (EGFR). The half-life is in the range of 7.5 days.
Indications
For the treatment of metastatic colorectal carcinoma.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity
- Interstitial lung disease or pulmonary fibrosis.
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include:
- Skin reactions
- Gastrointestinal disorders
- Fatigue, fever
- Lack of appetite
- Nail bed inflammation
